Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sight SciencesSGHT +5.36%66 Quick Ratio is 4.67 as of Jun. 2026, which is 53% below its 10-year median of 9.99. GuruFocus rates SGHT with a GF Score™ of 66/100 and a GF Value™ of $4.59 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Sight Sciences ranks better than 81.83% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Sight Sciences's quick ratio for the quarter that ended in Jun. 2026 was 4.67.
Sight Sciences has a quick ratio of 4.67. It generally indicates good short-term financial strength.
The historical rank and industry rank for Sight Sciences's Quick Ratio or its related term are showing as below:
SGHT'
s Quick Ratio Range Over the Past 10 Years
Min: 2.31 Med: 9.99 Max: 27.62
Current: 4.67
During the past 8 years, Sight Sciences's highest Quick Ratio was 27.62. The lowest was 2.31. And the median was 9.99.
SGHT's Quick Ratio is ranked better than 81.83% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 1.93
vs SGHT: 4.67
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Sight Sciences Quick Ratio Related Terms
Sight Sciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for Sight Sciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sight Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Sight Sciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a Quick Ratio of 4.67 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sight Sciences and its competitors. This is 53% below median its historical median of 9.99. Over the past decade, Sight Sciences' Quick Ratio has ranged from 2.31 to 27.62. According to the industry distribution chart, Sight Sciences ranks #155 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 18.2%.
Is Sight Sciences' Quick Ratio too high?
Sight Sciences' current Quick Ratio of 4.67 is 53% below median its 10-year median of 9.99. Over the past 10 years, this metric has ranged from a low of 2.31 to a high of 27.62. The Medical Devices & Instruments industry median Quick Ratio is 1.93. Sight Sciences' value of 4.67 is 142% above this industry median. Based on the distribution chart, Sight Sciences ranks #155 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sight Sciences has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Quick Ratio compare to TMCI and TLSI?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #155 out of 853 companies for Quick Ratio. This places Sight Sciences in the top 18% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.93. Sight Sciences' value of 4.67 is 142% above this benchmark. Historically, Sight Sciences' own Quick Ratio has ranged from 2.31 to 27.62 over the past decade. While the company's 10-year median is 9.99 vs. the industry median of 1.93, Sight Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.93, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sight Sciences's current Quick Ratio of 4.67 is 142% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current Quick Ratio is 4.67, which is 53% below median its own 10-year median of 9.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.59, compared to a current price of $7.48 — trading 63% above its estimated fair value. The current Quick Ratio is 4.67, which is 53% below median its 10-year median of 9.99 and 142% above the Medical Devices & Instruments industry median of 1.93. Sight Sciences' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Quick Ratio is 4.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $7.48 is trading 63% above its estimated GF Value™ of $4.59.
GuruFocus considers Sight Sciences to be Significantly Overvalued.
Key valuation signals for SGHT:
Quick Ratio: 4.67 (53% below median its 10-year median of 9.99)
GF Value™: $4.59 vs. price of $7.48 (63% above fair value)
Industry Position: 142% above the Medical Devices & Instruments median (#155 of 853)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
66GF Score
Get the complete analysis for SGHT
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
